5 Dividend Stocks to Buy According to Billionaire Kerr Neilson

3. Gilead Sciences, Inc. (NASDAQ:GILD)

Platinum Asset Management’s Stake Value: $101,892,000  

Percentage of Platinum Asset Management’s 13F Portfolio: 2.86%

Dividend Yield as of January 7: 3.93%

Gilead Sciences, Inc. (NASDAQ:GILD) is a biotech company that is focused on discovering, developing, and selling innovative medicines to cater to unmet medical needs across the globe. These medicines are discovered either through research or via acquisition.  The Foster City, California-based company’s antiviral drug Veklury (remdesivir) was one of the first treatments for COVID-19. This has given an impetus to the top line and the bottom line of the company.

Gilead Sciences, Inc. (NASDAQ:GILD) announced a quarterly dividend of 71 cents per share following its Q3 2021 results on October 28. The stock’s forward yield as of January 7 is 3.93%. In addition to this, Gilead Sciences, Inc. (NASDAQ:GILD) has a share buyback plan in place as well, which has reduced the total outstanding shares from 1.7 billion to 1.25 billion in the past five years.

On December 6, Salveen Richter at Goldman Sachs initiated coverage on Gilead Sciences, Inc. (NASDAQ:GILD) with a Neutral rating and an $82 price target. The analyst anticipates the company to stay as the dominant player in the HIV area due to its blockbuster HIV treatment Biktarvy. Furthermore, the analyst has highlighted the current evolution of Gilead Sciences, Inc. (NASDAQ:GILD) into a more diversified biopharma company.